Hope, despair and CRISPR — the race to save one woman’s life

Heidi Ledford

Nature, 2024, vol. 630, issue 8016, 284-288

Abstract: Researchers in India fought to develop what could have been the first therapy to use gene-editing to halt a rare neurodegenerative disease. The efforts hold lessons for the messy state of modern drug development.

Keywords: CRISPR-Cas9 genome editing; Biotechnology; Gene therapy; Medical research (search for similar items in EconPapers)
Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-024-01716-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:630:y:2024:i:8016:d:10.1038_d41586-024-01716-y

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-024-01716-y

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().